

FRIDAY, JANUARY 23, 2009

2:00 pm – 6:00 pm

Street Level Lobby

STS/AATS Tech-Con 2009 and STS 45th Annual Meeting On-Site Registration

SATURDAY, JANUARY 24, 2009

10:00 am – 6:00 pm

Street Level Lobby

STS/AATS Tech-Con 2009 and STS 45th Annual Meeting On-Site Registration

12:00 pm – 6:30 pm

Third Floor Lobby

STS/AATS Tech-Con 2009 Exhibits

1:00 pm – 2:45 pm

Room 3000

Joint Session: Cardiac & General Thoracic*Moderators: A. Marc Gillinov, Cleveland, OH and James D. Luketich, Pittsburgh, PA*

FINANCIAL DISCLOSURE A. Gillinov, principal investigator, Medtronic, principal investigator, St. Jude Medical, speaker, Medtronic, speaker, Edwards Lifesciences, speaker, St. Jude, equity, Viacor, consultant, Medtronic, consultant, St. Jude, consultant, Edwards Lifesciences; J.D. Luketich, principal investigator, Accuray, principal investigator, Covidien, principal investigator, Stryker, principal investigator, Oncotech, lecture fees, Stryker, lecture fees, Covidien, lecture fees, Axcant, stock options/recipient, Covidien, stock options/recipient, Axcant, stock options/recipient, Boston Scientific, stock options/recipient, Stryker, stock options/recipient, Alveolus, stock options/recipient, Intuitive Surgical

1:00 pm

Welcome and Introductions*A. Marc Gillinov, Cleveland, OH and James D. Luketich, Pittsburgh, PA*

1:05 pm

Robotic Surgery: A Key Part of Our Future (Debate)*Volkmar Falk, Leipzig, Germany and Francis Robicsek, Charlotte, NC*

1:45 pm

New Technology and Advances in Health Care: Can the United States Afford It?*Jeffrey B. Rich, Baltimore, MD*

2:05 pm

New Technology and Advances in Health Care: Can England Afford It?*Bruce E. Keogh, London, United Kingdom*

2:25 pm – 2:45 pm

Panel Discussion*A. Marc Gillinov, James D. Luketich, Volkmar Falk, Frances Robicsek, Jeffrey B. Rich, and Bruce E. Keogh*

2:45 pm - 3:15 pm

**Break - Visit STS/AATS Tech-Con 2009 Exhibits**

3:15 pm – 5:00 pm

Room 3000

Cardiac Track I: Coronary Revascularization*Moderator: Joseph F. Sabik, III, Cleveland, OH***FINANCIAL DISCLOSURE** J.F. Sabik, III, speaker bureau, Medtronic

3:15 pm

CABG vs. PCI (Pre-SYNTAX)*David P. Taggart, Oxford, United Kingdom*

3:32 pm

Conduits and Targets*Joseph F. Sabik, III, Cleveland, OH***FINANCIAL DISCLOSURE** J.F. Sabik, III, speaker bureau, Medtronic

3:49 pm

OPCAB: Is It a Better Strategy?*John D. Puskas, Atlanta, GA***FINANCIAL DISCLOSURE** J.D. Puskas, principal investigator, Maquet, principal investigator, Medtronic, scientific advisory board, Maquet, consultant, Medtronic

4:06 pm

Connectors: Ready for Prime Time?*Thomas A. Vassiliades, Atlanta, GA*

4:23 pm

Robotic CABG*Sudhir P. Srivastava, Chicago, IL***FINANCIAL DISCLOSURE** S.P. Srivastava, principal investigator, Intuitive Surgical, speaker bureau, Intuitive Surgical, speaker bureau, Cardica, consultant, Intuitive Surgical, consultant, Cardica, consultant, Novadaq

4:40 pm

Hybrid Revascularization*John G. Byrne, Nashville, TN***FINANCIAL DISCLOSURE** J.G. Byrne, research grant, Edwards Lifesciences, research grant, Medtronic, research grant, St. Jude Medical

3:15 pm – 5:00 pm

Room 3016 - 3018

General Thoracic Track I: Emerging Technologies in the Management of Esophageal Disease*Moderators: James D. Luketich, Pittsburgh, PA and Thomas J. Watson, Rochester, NY***FINANCIAL DISCLOSURE** J.D. Luketich, principal investigator, Accuray, principal investigator, Covidien, principal investigator, Stryker, principal investigator, Oncotech, lecture fees, Stryker, lecture fees, Covidien, lecture fees, Axcant, stock options/recipient, Covidien, stock options/recipient, Axcant, stock options/recipient, Boston Scientific, stock options/recipient, Stryker, stock options/recipient, Avleolus, stock options/recipient, Intuitive Surgical

3:15 pm

Welcome and Introductions*James D. Luketich, Pittsburgh, PA and Thomas J. Watson, Rochester, NY*

3:20 pm

Endoscopic Therapies for Barrett's Esophagus and Early Cancer*Thomas J. Watson, Rochester, NY*

3:35 pm

Debate: Endoscopic Therapies for Gastroesophageal Reflux Disease**Pro: Endoscopic Therapies Will Be the Standard***Blair A. Jobe, Pittsburgh, PA***FINANCIAL DISCLOSURE** B.A. Jobe, other research support, Sandhill, other research support, Olympus, other research support, Crospon, other research support, Endogastric Solutions, other research support, Torax Medical**Con: Surgical Fundoplication Is and Will Continue To Be the Standard***Steven R. DeMeester, Los Angeles, CA***FINANCIAL DISCLOSURE** S.R. DeMeester, consultant, Power Medical Interventions

4:05 pm

Panel Discussion*James D. Luketich, Thomas J. Watson, Blair A. Jobe, Steven R. DeMeester, and Julie A. Swain*

4:15 pm

Keynote Address: How to Design Device Studies: The FDA Perspective*Julie A. Swain, La Jolla, CA*

5:00 pm – 7:00 pm

Third Floor Lobby **STS/AATS Tech-Con 2009 Reception****SUNDAY, JANUARY 25, 2009**

7:00 am – 6:30 pm

*Street Level Lobby***STS/AATS Tech-Con 2009 and STS 45th Annual Meeting On-Site Registration**

7:00 am – 8:00 am

*Third Floor Lobby***STS/AATS Tech-Con 2009 Continental Breakfast**

7:00 am – 3:00 pm

*Third Floor Lobby***STS/AATS Tech-Con 2009 Exhibits**

8:00 am – 9:35 am

*Room 3000***Cardiac Track II: Session I: Valvular Heart Disease***Moderators: A. Marc Gillinov, Cleveland, OH and Friedrich W. Mohr, Leipzig, Germany***FINANCIAL DISCLOSURE** A.M. Gillinov, principal investigator, Medtronic, principal investigator, St. Jude Medical, speaker, Medtronic, speaker, Edwards Lifesciences, speaker, St. Jude Medical, equity, Viacor, consultant, Medtronic, consultant, St. Jude Medical, consultant, Edwards Lifesciences

8:00 am

Welcome and Introductions*A. Marc Gillinov, Cleveland, OH and Friedrich W. Mohr, Leipzig, Germany*

8:05 am

AVR: Prosthesis Choice*Tirone E. David, Toronto, ON, Canada***FINANCIAL DISCLOSURE** T.E. David, speaker at organized meetings, Medtronic, scientific advisory board on heart valves, Medtronic

8:20 am

Transcatheter AVR*Friedrich W. Mohr, Leipzig, Germany***REGULATORY DISCLOSURE** This presentation describes the use of Core Valves, Sapien Valve, and Ventor. They are currently in the FDA investigational status.

8:35 am

Mitral Repair Simplified Techniques*A. Marc Gillinov, Cleveland, OH***FINANCIAL DISCLOSURE** A.M. Gillinov, principal investigator, St. Jude Medical, principal investigator, Medtronic, speaker, Edwards Lifesciences, speaker, St. Jude Medical, equity, Viacor, consultant, Edwards Lifesciences, consultant, St. Jude Medical, consultant, Medtronic

8:50 am

Mitral Repair: Minimally Invasive Approaches*Aubrey C. Galloway, New York, NY***FINANCIAL DISCLOSURE** A.C. Galloway, research support, Medtronic, research support, Estech, intellectual property, Medtronic, intellectual property, Edwards Lifesciences, intellectual property, Estech, consultant, Medtronic, consultant, Edwards Lifesciences, consultant, Estech

9:05 am

Mitral Repair: Robotics*L. Wiley Nifong, Greenville, NC***FINANCIAL DISCLOSURE** L.W. Nifong, training consultant, Intuitive Surgical, advisor, Intuitive Surgical

9:20 am

Panel Discussion*Friedrich W. Mohr, Tirone E. David, A. Marc Gillinov, Aubrey C. Galloway, and L. Wiley Nifong*

9:35 am - 10:20 am

 **Break - Visit STS/AATS Tech-Con 2009 Exhibits**

8:00 am – 9:35 am

*Room 3016 - 3018***General Thoracic Track II: Session I****New Technologies in Lung Disease: From Endobronchial Valves to Tracer Technologies to Staging***Moderators: James D. Luketich, Pittsburgh, PA and Robert J. Cerfolio, Birmingham, AL***FINANCIAL DISCLOSURE** J.D. Luketich, principal investigator, Accuray, principal investigator, Covidien, principal investigator, Stryker, principal investigator, Oncotech, lecture fees, Stryker, lecture fees, Covidien, lecture fees, Axcan, stock options/recipient, Covidien, stock options/recipient, Axcan, stock options/recipient, Boston Scientific, stock options/recipient, Stryker, stock options/recipient, Alveolus, stock options/recipient, Intuitive Surgical; R.J. Cerfolio, speaker, E Plus Health Care, speaker, Ethicon, consultant, Neomend, speaker, Millicore, speaker, Medela, speaker, Teleflex (Eknatel), consultant, Closure (J&J), speaker, OSI Pharmaceuticals

8:00 am

Welcome and Introductions*James D. Luketich, Pittsburgh, PA and Robert J. Cerfolio, Birmingham, AL*

8:05 am

Endobronchial Valves for Emphysema*Douglas E. Wood, Seattle, WA***FINANCIAL DISCLOSURE** D.E. Wood, principal investigator for clinic trial, Spiration, consultant and steering committee for Current, Spiration, clinical trial**REGULATORY DISCLOSURE** This presentation describes the use Spiration and Emphyseus Intrabronchial Valve, which is in the FDA Investigational Status.

8:21 am

Radioisotope Tracer Technology for Localization of Small Pulmonary Nodules*Benjamin Kozowar, Charlottesville, VA*

8:36 am

Endobronchial Ultrasound and EUS**Pro: EBUS and EUS Will Be the Standard***Rafael S. Andrade, Minneapolis, MN***Con: Mediastinoscopy Is Still Necessary***James D. Luketich, Pittsburgh, PA***FINANCIAL DISCLOSURE** J.D. Luketich, principal investigator, Accuray, principal investigator, Covidien, principal investigator, Stryker, principal investigator, Oncotech, lectures fees, Stryker, lectures fees, Covidien, lectures fees, Axcan, stock options/recipient, Covidien, stock options/recipient, Axcan, stock options/recipient, Boston Scientific, stock options/recipient, Stryker, stock options/recipient, Alveolus, stock options/recipient, Intuitive Surgical

Sunday, January 25, 2009 – Continued

9:00 am

Lung Cancer Staging: PET and Beyond*Robert J. Cerfolio, Birmingham, AL***FINANCIAL DISCLOSURE** R.J. Cerfolio, speaker, E Plus Health Care, speaker, Ethicon, consultant, Neomend, speaker, Millicore, speaker, Medela, speaker, Teleflex (Eknatell), consultant, Closure (J&J), speaker, OSI Pharmaceuticals

9:15 am

Panel Discussion*James D. Luketich, Douglas E. Wood, Robert J. Cerfolio, Rafael S. Andrade, and Benjamin Kozower*

9:35 am – 10:20 am

 **Break - Visit STS/AATS Tech-Con 2009 Exhibits**

10:20 am – 11:35 am

Room 3000

Cardiac Track II: Session II: Endovascular and Aortic Therapies*Moderators: Joseph E. Bavaria, Philadelphia, PA and Lars G. Svensson, Cleveland, OH***FINANCIAL DISCLOSURE** J.E. Bavaria, primary investigator, W.L. Gore & Associates, consulting agreement, W.L. Gore & Associates, co-primary investigator, Medtronic

10:20 am

Descending and Thoracoabdominal Aneurysms*Joseph E. Bavaria, Philadelphia, PA***FINANCIAL DISCLOSURE** J.E. Bavaria, primary investigator, W.L. Gore & Associates, co-primary investigator, Medtronic, consulting agreement, W.L. Gore & Associates, speakers bureau, Medtronic**REGULATORY DISCLOSURE** This presentation describes GORE TAG, which is approved by the FDA, and Medtronic Valiant which is still investigational by the FDA. This presentation describes the off-label use of these devices in aortic dissection.

10:35 am

Management of Aortic Arch Pathology*Joseph S. Coselli, Houston, TX***FINANCIAL DISCLOSURE** J.S. Coselli, principal investigator, St. Jude Medical, principal investigator, Cook, principal investigator, Medtronic, consultant, Baxter Medication Delivery, consultant, Edwards Lifesciences, consultant, Terumo Cardiovascular**REGULATORY DISCLOSURE** This presentation describes the off-label of a patient case involving hybrid arch repairs, whereas, the devices are approved for descending thoracic aortic repair.

10:50 am

Stenting the Ascending Aorta*Grayson H. Wheatley, III, Phoenix, AZ***FINANCIAL DISCLOSURE** G.H. Wheatley, principal investigator, W.L. Gore and Associates, scientific advisory board, W.L. Gore and Associates, consultant, Medtronic**REGULATORY DISCLOSURE** This presentation describes the use of GORE TAG Non Branchial, which is FDA approved, GORE TAG Branchial which is not FDA approved, and Medtronic Talent, which is FDA approved. This presentation describes the off-label use of the stenting of ascending aorta which is not approved.

11:05 am

Valve-Sparing Aortic Root Surgery*Lars G. Svensson, Cleveland, OH*

11:20 am

Endovascular Therapy for Dissections*Eric E. Roselli, Cleveland, OH***FINANCIAL DISCLOSURE** E.E. Roselli, principal investigator, Medtronic, consultant, Medtronic**REGULATORY DISCLOSURE** This presentation describes the GORE TAG stent graft, which is FDA approved, the Cook TX stent graft which the IDE version is in the investigational FDA status, and the Medtronic Talent and Valiant Stent graft, which are in the investigational FDA status. This presentation describes the off-label use of stent grafts for dissections.

11:45 am – 1:00 pm

Room 2001

 **Networking Lunch**

10:20 am – 11:35 am

Room 3016 - 3018

General Thoracic Track II: Session II: What's New in Lung Cancer Treatment*Moderators: James D. Luketich, Pittsburgh, PA and Richard I. Whyte, Stanford, CA***FINANCIAL DISCLOSURE** J.D. Luketich, principal investigator, Accuray, principal investigator, Covidien, principal investigator, Stryker, principal investigator, Oncotech, lecture fees, Stryker, lecture fees, Covidien, lecture fees, Axcan, stock options/recipient, Covidien, stock options/recipient, Axcan, stock options/recipient, Boston Scientific, stock options/recipient, Alveolus, stock options/recipient, Intuitive Surgical

10:20 am

Debate: Treatment for Early Stage Non-Small Cell Lung Cancer (NSCLC)**Pro: A Trial of Stereotactic Radiosurgery for Stage I NSCLC: The Time is Now***Jack A. Roth, Houston, TX***FINANCIAL DISCLOSURE** J.A. Roth, principal investigator, STARS Clinical Trial, Accuray**Con: Lobectomy Is the Standard Treatment***Thomas A. D'Amico, Durham, NC***FINANCIAL DISCLOSURE** T.A. D'Amico, speaker, Covidien, consultant, Scanlan Group

10:40 am

Ablative Technologies for Lung Cancer*Arjun Pennathur, Pittsburgh, PA***FINANCIAL DISCLOSURE** A. Pennathur, co-investigator, grant to university, Rita Medical/Angiodynamics**REGULATORY DISCLOSURE** This presentation describes the use of Radiofrequency, which is FDA approved. Radiofrequency Ablation is approved by the FDA for soft tissue lesions, not specifically for lung lesions.

11:00 am

Endobronchial and Transthoracic Navigational Technologies*Hiran C. Fernando, Boston, MA***FINANCIAL DISCLOSURE** H.C. Fernando, research grant, Valleylab, research grant, Vera Medical Technologies, research grant, AngioDynamics, speaker bureau, Boston Scientific, speaker bureau, Axcan Pharma, stock options, Vera Medical Technologies

11:10 am

Keynote Address: Simulators in Cardiothoracic Surgical Education*Richard H. Feins, Chapel Hill, NC*

11:45 am – 1:00 pm

Room 2001

 **Networking Lunch**

1:15 pm – 4:30 pm

Room 3014

 **STS Parallel Surgical Symposium: Congenital**

1:15 pm – 4:30 pm

Room 3016 - 3018

 **STS Parallel Surgical Symposium: General Thoracic**

1:15 pm – 2:30 pm**Room 3000****Cardiac Track III: Atrial Fibrillation****Moderators:** *Ralph J. Damiano, St. Louis, MO and Nicolas Doll, Leipzig, Germany***FINANCIAL DISCLOSURE** R.J. Damiano, principal investigator, Estech, principal investigator, AtriCure, principal investigator, nContact Surgical, speaker, Estech, consultant/advisory board, AtriCure, consultant/advisory board, Medtronic, consultant/advisory board, ATS Medical; N. Doll, consultant, AtriCure, advisory board, St. Jude Medical**REGULATORY DISCLOSURE** This presentation describes the off-label use of the AtriCure ablation device and the Medtronic ablation device used to treat atrial fibrillation.**1:15 pm****Ablation Technologies: Real Differences?***Nicolas Doll, Leipzig, Germany***FINANCIAL DISCLOSURE** N. Doll, consultant, AtriCure, advisory board, St. Jude Medical**1:30 pm****Stand-Alone Surgical Ablation***James R. Edgerton, Plano, TX***FINANCIAL DISCLOSURE** J.R. Edgerton, principal investigator, AtriCure, speaker honoraria, AtriCure**REGULATORY DISCLOSURE** AtriCure ablation devices, some have a cardiac indication but not specifically for atrial fibrillation.**1:45 pm****Concomitant Ablation Strategies***Ralph J. Damiano, St. Louis, MO***FINANCIAL DISCLOSURE** R.J. Damiano, principal investigator, Estech, principal investigator, AtriCure, principal investigator, nContact Surgical, speaker, Estech, consultant/advisory board, AtriCure, consultant/advisory board, Medtronic, consultant/advisory board, ATS Medical**REGULATORY DISCLOSURE** This presentation describes the off-label use of the AtriCure ablation device and the Medtronic ablation device used to treat atrial fibrillation.**2:00 pm****The Left Atrial Appendage: Our Next Target?***A. Marc Gillinov, Cleveland, OH***FINANCIAL DISCLOSURE** A.M. Gillinov, principal investigator, St. Jude Medical, principal investigator, Medtronic, speaker, Edwards Lifesciences, speaker, St. Jude Medical, speaker, Medtronic, Cleveland Clinic has an indirect equity interest, AtriCure, consultant, Edwards Lifesciences, consultant, St. Jude Medical, consultant, Medtronic**REGULATORY DISCLOSURE** This presentation describes the left atrial appendage occlusion device in clinical trials. They are not FDA approved or commercially available in the United States.**2:15 pm****Surgical Ablation: The Real Results***Niv Ad, Falls Church, VA***FINANCIAL DISCLOSURE** N. Ad, speaker bureau, ATS Medical, owner, AFM Medical, principal investigator, AtriCure, advisory board, ATS Medical, advisory board, Medtronic**2:30 pm - 3:00 pm****Break - Visit STS/AATS Tech-Con 2009 Exhibits****3:00 pm – 4:30 pm****Room 3000****Cardiac Track IV: Heart Failure****Moderators:** *John V. Conte, Baltimore, MD and Nicholas G. Smedira, Cleveland, OH***FINANCIAL DISCLOSURE** J.V. Conte, principal investigator, Thoratec, principal investigator, Abiomed, train centers to use LVADs, Thoratec, train centers to use LVADs, Abiomed; N.G. Smedira, paid proctor, Syncardia**3:00 pm****Surgical Ventricular Restoration***John V. Conte, Baltimore, MD***FINANCIAL DISCLOSURE** J.V. Conte, principal investigator, Thoratec, principal investigator, Abiomed, train centers to use LVADs, Thoratec, train centers to use LVADs, Abiomed**3:18 pm****Ventricular Assist Devices: Patient and Pump Selection***Nicholas G. Smedira, Cleveland, OH***FINANCIAL DISCLOSURE** N.G. Smedira, paid proctor, Syncardia**3:36 pm****Ventricular Assist Devices: Getting Smaller all the Time***Benjamin C. Sun, Columbus, OH***FINANCIAL DISCLOSURE** B.C. Sun, lecture/education, Abiomed, lecture/education, St. Jude Medical, lecture/education, Thoratec, consultant, Thoratec**REGULATORY DISCLOSURE** This presentation describes the use of Heartware LVAD, Heartware II LVAD, and VentrAssist LVAD, which are in FDA investigation status.**3:54 pm****Advances in Preservation for Heart Transplant***Tomislav Mihaljevic, Cleveland, OH***FINANCIAL DISCLOSURE** T. Mihaljevic, co-investigator in clinical trials, TransMedics**REGULATORY DISCLOSURE** This presentation describes the use of TransMedics device, which is in the FDA investigational status.**4:12 pm****Ventricular Restraint Devices***Michael A. Acker, Philadelphia, PA***FINANCIAL DISCLOSURE** M.A. Acker, consultant, Acorn Cardiovascular**4:30 pm – 6:30 pm****Exhibit Hall, Street Level****Opening Reception**